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Background: The immunohistochemical detection of Enhancer of zeste homologue 2 (EZH2) proved to be a useful
tool to recognize the malignant nature of tumors in a wide variety of neoplasms. The histological diagnostics of
salivary gland tumors is a challenging task, and a reliable marker of malignancy would be extremely helpful.
Methods: EZH2 expression was investigated in 54 malignant and 40 benign salivary gland tumors of various histological
types by standard immunohistochemistry.
Results: The majority (n = 52) of the malignant tumors stained positively, while all the investigated benign tumors were
negative for EZH2.
Conclusions: EZH2 expression in salivary gland tumors, similarly to the tumors of other organs is not characteristic for
any tumor type, but is a solid marker of the malignant nature of the tumors.Background
Although tumors of the salivary glands are not among
the most common neoplasms, they provide a serious
challenge for pathologists. The multitude of tumor types
and overlapping histological features often give rise to
multiple interpretations. Moreover, on occasion it can be
problematic to distinguish between the benign and ma-
lignant nature of certain specimens. Of course, ancillary
techniques are widely used. Certain molecular lesions
have been recognized in different tumors and immuno-
histochemistry is applied on an everyday routine basis
[1–3]. However, these techniques provide only limited
help and the diagnosis is mostly determined by the H&E
stained sections.
Enhancer of zeste homologue 2 (EZH2) is a widely
studied histone methyl transferase [4, 5]. Recently we
have reported that the immunohistochemical examin-
ation of this protein can effectively distinguish between
benign and malignant hepatic tumors [6]. Similar obser-
vations have been made in intraductal papillary neo-
plasms of bile ducts [7], effusion cytology [8], etc. To
our knowledge, there is quite limited information on the* Correspondence: pdrnagy@gmail.com
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gland tumors. The available data, however, suggest that
there may be a connection between the behavior of sal-
ivary gland tumors and EZH2 expression as well [9, 10].
The purpose of our study is to examine EZH2 expres-
sion in a variety of benign and malignant salivary gland
tumors, and to investigate if it provides any useful infor-
mation for their recognition. All 40 benign salivary gland
tumors investigated were negative for EZH2, while 52 of
the 54 malignant tumors proved to be positive. Based on
this observation EZH2 immunohistochemistry might
provide valuable information for the histological examin-
ation of salivary gland tumors.
Methods
We selected 54 (Additional file 1: Table S1) malignant
and 40 benign (Additional file 2: Table S2) salivary
gland tumors from the archives of the First Depart-
ment of Pathology and Experimental Cancer Research,
Semmelweis University (Budapest, Hungary) and Path-
ology Department of National Institute of Oncology
(Budapest, Hungary). The study was approved by the
ethics committee of the Semmelweis University. The
tumors were diagnosed according to standard diag-
nostic criteria and immunohistochemical staining.
Formalin-fixed paraffin-embedded tissue was used forhis article is distributed under the terms of the Creative Commons Attribution
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formed using an automated Leica Bond immunostai-
ner, with the Leica Bond Polymer refine detection system
and 3,3′ Diaminobenzidine (DAB) as the chromogen.
Antigen retrieval was achieved with Bond Epitope Re-
trieval Solution 2 (high pH) for 20 min. The primary
antibody was a mouse monoclonal anti-EZH2 (clone
11/EZH2) from BD Biosciences (San Jose CA, USA)
(dilution 1:100). The reaction resulted in nuclear
staining. Scores were assigned based on the density of
positivity by using negative (score =0, < 5 % of nuclei
staining); weak (score = 1, 5–10 % of nuclei staining);
moderate (score = 2, 11–50 % of nuclei staining); and
strong (score = 3; >50 % of nuclei staining).Results
EZH2 immunohistochemical staining resulted in a clear
nuclear reaction. The non-tumorous portion of the saliv-
ary gland tissue always remained negative. The lymphoid
cells were frequently positive, as well as the nuclei of the
squamous epithelium on occasional mucosal pieces on
the tissue.Benign tumors
The 18 investigated pleiomorphic adenomas (Fig. 1a
and b) included a wide range of this highly variable
tumor type. Two of the specimens were recurrent multi-
focal tumors, but regardless of the actual structure,
were consistently negative for EZH2. Occasionally
scattered EZH2 positive nuclei were present in theFig. 1 H & E (a) and EZH2 staining (b) of a pleiomorphic adenoma (40x); th
H & E (c) and EZH2 staining (d) of a Warthin tumor (40x); the epithelial compo
positive for EZH2epithelial component, but the ratio of these marked
nuclei was always under 5 %.
The epithelial components of the Warthin tumors
(Fig. 1c and d) were also consistently negative, while the
lymphoid follicles, especially the germinative centers,
were stained for EZH2 similar to the normal lymphoid
tissue. Thus, these tumors were regarded as negative,
not unlike other less common benign tumors such as
basal cell adenomas, oncocytomas and cystadenomas.Malignant tumors
Mucoepidermoid carcinoma (Fig. 2a and b) is the
most common malignant tumor of the salivary glands.
This tumor type was represented in the highest frequency
(n = 17) of all the tumors studied. All but one of the inves-
tigated tumors stained positively for EZH2. The negative
tumor was a small preoperative excision. Since EZH2 ex-
pression is mostly focal in the tumors, this negative result
may be the consequence of a sampling error. Immuno-
staining was usually more extensive in the epidermoid
component. No reliable relationship could be observed
with tumor grade, but poorly differentiated components
with infiltrative growth pattern were also positive.
All the studied adenoid cystic carcinomas (n = 13)
stained positively with EZH2 antibody (Fig. 2c and d).
The growth pattern of the tumor had no influence on
the staining. Preferential staining of the abluminal cells
could be observed in a few tumors, but this feature was
not consistent. Perineural invading components of the
tumors were also positive.ere are only scattered positive nuclei in all components of the tumor;
nent of the tumor is negative, while the lymphocytes are frequently
Fig. 2 H & E (a) and EZH2 staining (b) of the fat tissue around a mucoepidermoid carcinoma (80x); the EZH2 reaction nicely reveals the scattered
tumor cells; H & E (c) and EZH2 staining (d) of an adenoid cystic carcinoma (80x); EZH2 positive nuclei are common
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cluded. All were adenocarcinomas: one with focal squa-
mous differentiation, one with dominant adenoid cystic
carcinoma and another with malignant myoepithelioma
components. Regardless of the histological structure,
they were positive for EZH2 (Fig. 3a and b). One of the
sections contained a preexistent adenoma which remained
negative. The lymph node metastasis of a poorly differen-
tiated adenocarcinoma was also positive.Fig. 3 H & E (a) and EZH2 staining (b) of a poorly differentiated carcinoma
surrounding normal salivary gland remains negative; H & E (c) and EZH2 st
a heterogeneous staining for EZH2, but more than 20 % of the nuclei are pFour of the acinic cell carcinomas (n = 5) had micro-
cystic growth pattern, with one showing occasional pap-
illary structures. All were variably positive. The single
solid acinic cell carcinoma had, however, very few posi-
tively stained nuclei which was below our 5 % threshold.
The three polymorphous low grade adenocarcinomas
stained positively (Fig. 3c and d).
In case of two myoepithelial and one basal cell tumors,
the malignant diagnosis was based on the high mitoticex pleiomorphic adenoma (40x); the tumor is strongly positive, the
aining (d) of a polymorphous low-grade adenocarcinoma (80x); there is
ositive
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ses were nicely supported by the positive EZH2 staining.
Three non-classifiable adenocarcinomas, one squamous
cells carcinoma and one clear cell carcinoma also stained
positively.
Discussion
We have investigated the expression of EZH2 by immu-
nohistochemistry on the most common types of salivary
gland tumors. All the benign tumors (n = 40) were nega-
tive, but the majority of the malignant tumors (52/54)
regardless of the histological type proved to be positive.
EZH2 is the catalytic subunit of polycomb repressive
complex 2 (PRC2). It catalyzes the trimethylation of ly-
sine 27 on histone H3 (H3K27me3), and mediates tran-
scriptional silencing [4, 5]. Gain of function mutations of
EZH2 represent a promising therapeutic target in germi-
nal center lymphomas [11], and increased expression of
this protein has been reported in several other tumors
[12–19]. It is usually an unfavorable prognostic marker.
We have described that EZH2 is expressed in most of the
malignant liver tumors, but it is absent from the benign
tumors and reactive proliferative lesions [6]. This reaction
was useful to recognize the malignant behavior of intra-
ductal papillary neoplasms of bile ducts [7], hepatic and
pancreatic cystic neoplasms [20] and squamous cell tu-
mors of the skin [21]. EZH2 proved to be a unique marker
of malignancy in effusion cytology [8]. Such a reliable
marker of malignant tumors would be extremely helpful
for salivary gland tumors as well due to their diverse histo-
logical structure, and the common morphological overlap
between benign and malignant tumors. Assessment of
proliferative activity [22] and several other markers
(Human α-defensin, maspin, RB1-inducible coiled-coil
1, etc.) [2, 23–25] has been proposed to address this prob-
lem. High expression of EZH2 detected by immunohisto-
chemistry has been reported to predict poor survival for
patients with adenoid cystic carcinoma [9]. Increased
EZH2 staining was more common in malignant myoe-
pithelial tumors [10]. High expression of H3K9me3 is a
strong predictor of poor survival in patients with salivary
adenoid cystic carcinoma [26]. Although this DNA modi-
fication is related with another enzyme, it may indicate
that the activity of histone methylation might be con-
nected with the biological behavior of salivary gland tu-
mors. As far as we know, our study is the first to involve a
comprehensive set of salivary gland tumors. Our finding is
comparable to the result found on other types of tumors.
EZH2 is a highly sensitive (96.3 %) and specific (100 %) in-
dicator of malignancy in salivary gland tumors. According
to our results its positive predictive value is 100 %, while
its negative predictive value is 95.24 %. The increased ex-
pression of this enzyme cannot be associated with any
specific cell type, and so, similarly to the tumors of otherorgans, it does not provide any help for the histological
classification of the tumors. Our sample size for the indi-
vidual tumor types is too low to search for connection be-
tween the level of overexpression and prognosis. It is also
crucial to investigate large series of tumors (e.g. basal cell
adenoma v.s. carcinoma, myoepithelial, oncocytic tumors)
where there is a broad gray border zone between benign
and malignant tumors making the distinction between
them highly challenging. Our result indicates that it would
be worth performing such studies along with elucidating
the molecular mechanism of EZH2 upregulation in saliv-
ary gland tumors. Such studies are most advanced in case
of follicular lymphomas, where EZH2 has become a po-
tential target of therapeutic approaches [11].
Interestingly, increased EZH2 expression has been re-
ported in oral squamous cell carcinomas compared to
dysplastic and normal epithelium [27]. The judgment of
the squamous epithelium is another shaky field of oral
pathology. In our slides the accidental non tumorous
epithelium was always strongly decorated by the EZH2
antibody.
Conclusion
In conclusion, the majority of malignant salivary gland
tumors is EZH2 positive. This immunohistochemical re-
action may be a useful tool to recognize them; however,
it does not help to distinguish between different varieties
of salivary gland carcinomas.
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